Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642893 | 0.79 | KDM4E (0.36) | LMNAMAPTKDM4EPKMMAPK1 | |
| SCHEMBL2643099 | 0.78 | ADORA2A (0.38) | LMNAMAPTKDM4EPKMMAPK1 | |
| SCHEMBL2642043 | 0.73 | GCK (0.40) | LMNAMAPK1KMT2ANPSR1POLB | |
| SCHEMBL5658428 | 0.62 | APOBEC3G (0.52) | LMNAMAPTKDM4EPKMMAPK1 | |
| SCHEMBL14529160 | 0.61 | ADORA2A (0.51) | LMNAMAPTKDM4EPKMMAPK1 | |
| SCHEMBL14266706 | 0.61 | APP (0.58) | LMNAMAPTKDM4EPKMMAPK1 | |
| SCHEMBL24795860 | 0.60 | NPC1 (0.56) | LMNAMAPTKDM4EKMT2ATP53 | |
| SCHEMBL8536641 | 0.60 | CYP2C9 (0.66) | LMNAMAPK1KMT2APOLB | |
| SCHEMBL8531787 | 0.60 | CYP2C9 (0.49) | LMNA | |
| SCHEMBL9472324 | 0.60 | APOBEC3G (0.61) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | LMNA 4577/4885MAPT 4375/4885KDM4E 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.